NCT04065581 - Bioequivalence Study for Acarbose/Metformin FDC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

November 25, 2019

Study Completion Date

March 6, 2020

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Acarbose/Metformin FDC(BAY81-9783)

Single dose: 50 mg acarbose/500 mg metformin tablet, oral

DRUG

Glucobay

Single dose: 50 mg tablet, oral

DRUG

Glucophage

Single dose: 500 mg tablet, oral

Trial Locations (1)

Zhongshan Hospital, Fudan University, Shanghai